The $130M Bet That CGRP Isn't the Only Way to Fight Migraines

The drug itself, SLTE-1009, was licensed from DartsBio Pharmaceuticals in China. Financial terms of that deal weren't disclosed. Slate is headquartered in Raleigh, North Carolina, and also has an undisclosed second program in its pipeline.

The PACAP Graveyard (and Why Slate Thinks It's Different)

Slate isn't the first company to chase PACAP. And the history here is, well, humbling.

Amgen tried it with AMG 301, an anti-PAC1 receptor antibody that reached Phase 2a trials before failing to hit its goals around 2019-2020. The program was scrapped. Alder Biopharmaceuticals had its own candidate, ALD1910, which entered Phase 1 but whose development stalled after Lundbeck acquired Alder.

So why try again? Two reasons stand out.

First, Lundbeck's AG09222 has since completed Phase 2 trials with positive results, validating that the PACAP target can actually work in patients when the drug is designed right. Lundbeck is now prepping for Phase 3, likely making AG09222 the most advanced anti-PACAP program in the world. That's a meaningful proof point for Slate: the target isn't broken, earlier attempts just didn't nail the execution.

Second, SLTE-1009 was engineered with half-life extension technology designed for subcutaneous (under-the-skin) injection at home. That's a practical advantage. Patients don't need to visit a clinic. The convenience factor matters enormously for a preventive therapy that people take long-term.

A Large and Growing Market With Room for More

The migraine prevention market is large and growing fast. The real money is in preventive drugs patients take month after month.

But size alone doesn't guarantee opportunity. What matters is whether PACAP-targeting drugs can carve out a distinct patient population. If a meaningful chunk of migraine sufferers don't respond to CGRP blockers (and clinical experience suggests many don't), a drug working through a completely independent pathway could become the go-to second option.

That's the pitch: not replacing CGRP drugs, but catching the patients they miss.

The Road Ahead Is Long

Let's be honest about timelines. SLTE-1009 is still preclinical. Phase 1 trials aren't expected until mid-2026, meaning the earliest this drug could reach patients is likely 2029 or 2030 at the absolute fastest. A lot can go wrong between now and then.

Slate will also need to contend with Lundbeck's AG09222, which has a significant head start. If Lundbeck's Phase 3 succeeds, it could reach the market years before Slate's drug does. Being second to market in an emerging class isn't fatal (Ajovy and Emgality both thrived despite launching after Aimovig), but it does raise the bar for differentiation.

The $130 million war chest should fund Slate through early clinical development, but a Phase 3 migraine trial will require substantially more capital. Expect another major fundraise, or a partnership with a larger pharma company, before this story reaches its conclusion.

The Bottom Line

Slate Medicines is making a big, well-funded bet that the migraine prevention market needs a second act beyond CGRP. The science supporting PACAP as a target has matured considerably since Amgen's failed attempt, and Lundbeck's positive Phase 2 data provides real validation.

With experienced leadership, top-tier investors, and a drug designed for convenient at-home dosing, Slate has assembled the right ingredients. Whether they can bake them into something patients actually benefit from won't be clear for years. But for the millions of migraine sufferers who've tried CGRP drugs and come up short, the mere existence of a credible alternative is worth watching closely.